AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35809011 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 51
Study 33278626 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led, goal-directed lung physiotherapy
Number of subjects: 201
Study 33278626 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy for sepsis
Number of subjects: 201
Study 34698353 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormadinone
Number of subjects: 143
Study 34698353 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 143
Study 32321477 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 60
Study 32321477 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (E-TAU)
Number of subjects: 60
Study 35179551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin (0.4 mg/kg body weight daily for 5 days) + standard of care
Number of subjects: 490
Study 35179551 — intervention group
Group type: COMPARATOR
Intervention: Standard of care alone
Number of subjects: 490
Study 32117545 — intervention group
Group type: COMPARATOR
Intervention: Standard Ponseti casting technique (once-weekly)
Number of subjects: 100
Study 32117545 — intervention group
Group type: EXPERIMENTAL
Intervention: Accelerated Ponseti casting technique (twice-weekly)
Number of subjects: 100
Study 35904872 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality Hypnosis (VRH)
Number of subjects: 60
Study 35904872 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 60
Study 34127852 — intervention group
Group type: EXPERIMENTAL
Intervention: Danuglipron (PF-06882961)
Number of subjects: 98
Study 34127852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 32656934 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time PCR followed by high-resolution melting analysis (HRMA)
Number of subjects: 232
Study 36089068 — intervention group
Group type: EXPERIMENTAL
Intervention: Selexipag
Number of subjects: 108
Study 36089068 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 108
Study 32063564 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐Carnosine 400 mg twice daily
Number of subjects: 58
Study 32063564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study 32063564 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐Carnosine
Number of subjects: 58
Study 32687220 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher empathy after induced happiness
Number of subjects: 218
Study 32687220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower empathy after induced sadness
Number of subjects: 218
Study 32687220 — intervention group
Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 218
Study 33566465 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin prophylaxis started less than 24 hours after insertion of central venous catheter, adjusted to anti-Xa level of 0.2-0.5 international units/mL
Number of subjects: 51
Study 33566465 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 51
Study 36108676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B complex supplementation (thiamine 10 mg, riboflavin 4 mg, nicotinamide 40 mg, dexpanthenol 6 mg)
Number of subjects: 85
Study 36108676 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar nutritional supports without group B vitamins)
Number of subjects: 85
Study 36108676 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B complex supplementation
Number of subjects: 85
Study 33239268 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0
Study 33239268 — intervention group
Group type: COMPARATOR
Intervention: Control (standard treatment)
Number of subjects: 0
Study 32645831 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate
Number of subjects: 47
Study 32645831 — intervention group
Group type: EXPERIMENTAL
Intervention: Citrate + Theobromine
Number of subjects: 47
Study 36125471 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg, n=51)
Number of subjects: 101
Study 36125471 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=50)
Number of subjects: 101
Study 34052685 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate (N = 39)
Number of subjects: 65
Study 34052685 — intervention group
Group type: COMPARATOR
Intervention: Placebo (N = 26)
Number of subjects: 65
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Prass standard monopolar stimulator
Number of subjects: 11
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar stimulator
Number of subjects: 11
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissecting instrument
Number of subjects: 11
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Ball tip stimulator
Number of subjects: 11
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled mean latency
Number of subjects: 11
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled mean threshold
Number of subjects: 11
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled mean saturation
Number of subjects: 11
Study 32176321 — intervention group
Group type: EXPERIMENTAL
Intervention: Monopolar electrodes
Number of subjects: 11
Study 34131878 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal message reminder with self-scheduling option (n=5408)
Number of subjects: 16728
Study 34131878 — intervention group
Group type: EXPERIMENTAL
Intervention: Portal message reminder only (n=5699)
Number of subjects: 16728
Study 34131878 — intervention group
Group type: COMPARATOR
Intervention: Control group (no portal message) (n=5621)
Number of subjects: 16728
Study 34131878 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between self-scheduling and message only groups
Number of subjects: 16728
Study 33548492 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 41
Study 33548492 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 32178964 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (840 mg) plus nab-paclitaxel (100 mg/m2)
Number of subjects: 0
Study 32178964 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nab-paclitaxel (100 mg/m2)
Number of subjects: 0
Study 35675795 — intervention group
Group type: EXPERIMENTAL
Intervention: AO + PES
Number of subjects: 34
Study 35675795 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-AO + continuous PES
Number of subjects: 34
Study 35675795 — intervention group
Group type: EXPERIMENTAL
Intervention: BCI-AO + triggered PES
Number of subjects: 34
Study 35675795 — intervention group
Group type: COMPARATOR
Intervention: AO alone
Number of subjects: 34
Study 32822325 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional yoghurt (300 grams daily for 8 weeks)
Number of subjects: 37
Study 32822325 — intervention group
Group type: COMPARATOR
Intervention: Organic yoghurt (300 grams daily for 8 weeks)
Number of subjects: 37
Study 32822325 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Conventional and Organic yoghurt)
Number of subjects: 37
Study 36283011 — intervention group
Group type: EXPERIMENTAL
Intervention: Etelcalcetide
Number of subjects: 203
Study 36283011 — intervention group
Group type: COMPARATOR
Intervention: Control (historical group)
Number of subjects: 203
Study 34018637 — intervention group
Group type: COMPARATOR
Intervention: Prognostic Nutritional Index (PNI)
Number of subjects: 5839
Study 32077305 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Branding intervention in bars and nightclubs (anti-tobacco messages through events, opinion leaders, art, direct mail, promotional activities, online media)
Number of subjects: 7240
Study 32077305 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Branding intervention in bars and nightclubs
Number of subjects: 7240
Study 32077305 — intervention group
Group type: COMPARATOR
Intervention: Control group (Los Angeles)
Number of subjects: 7240
Study 32077305 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Branding intervention
Number of subjects: 7240
Study 35786577 — intervention group
Group type: EXPERIMENTAL
Intervention: Endosequence Bioceramic Sealer (BCS)
Number of subjects: 64
Study 35786577 — intervention group
Group type: COMPARATOR
Intervention: AH Plus (AHP)
Number of subjects: 64
Study 34138761 — intervention group
Group type: EXPERIMENTAL
Intervention: taVNS
Number of subjects: 42
Study 34138761 — intervention group
Group type: COMPARATOR
Intervention: sham-taVNS
Number of subjects: 42
Study 32727707 — intervention group
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Number of subjects: 49
Study 32727707 — intervention group
Group type: COMPARATOR
Intervention: Observation
Number of subjects: 49
Study 32727707 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline soluble mesothelin-related peptide
Number of subjects: 49
Study 34254218 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise group (AEG, n = 11) performing aerobic exercise on an adapted exercise bike three times a week for three months (36 sessions)
Number of subjects: 20
Study 34254218 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise group (REG, n = 14) performing resistance exercise using elastic bands and ankle cuffs three times a week for six months (72 sessions)
Number of subjects: 20
Study 34254218 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 9 for AEG and n = 12 for REG)
Number of subjects: 20
Study 34571336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12)
Number of subjects: 294
Study 34571336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12 followed by subsequent response)
Number of subjects: 294
Study 34571336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12 followed by no change in response or progression)
Number of subjects: 294
Study 34571336 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (with initial stable disease at week 12 followed by progression before week 24)
Number of subjects: 294
Study 34388424 — intervention group
Group type: EXPERIMENTAL
Intervention: HV night splint (SP)
Number of subjects: 60
Study 34388424 — intervention group
Group type: COMPARATOR
Intervention: Exercise (EX)
Number of subjects: 60
Study 34388424 — intervention group
Group type: COMPARATOR
Intervention: High-voltage galvanic stimulation (HVPGS) (EL)
Number of subjects: 60
Study 35299084 — intervention group
Group type: EXPERIMENTAL
Intervention: FeZnPM (iron- and zinc-biofortified pearl millet)
Number of subjects: 223
Study 35299084 — intervention group
Group type: COMPARATOR
Intervention: CPM (conventional non-biofortified pearl millet)
Number of subjects: 223
Study 32236404 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 45
Study 33328044 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT-I
Number of subjects: 1721
Study 33328044 — intervention group
Group type: COMPARATOR
Intervention: Patient education
Number of subjects: 1721
Study 34524565 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxonidine
Number of subjects: 114
Study 34524565 — intervention group
Group type: COMPARATOR
Intervention: Bisoprolol
Number of subjects: 114
Study 33079754 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular percutaneous electrical nerve field stimulation
Number of subjects: 0
Study 33079754 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 35125129 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing First (HF)
Number of subjects: 703
Study 35125129 — intervention group
Group type: COMPARATOR
Intervention: Treatment-As-Usual (TAU)
Number of subjects: 703
Study 34073134 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat exposure (35 °C)
Number of subjects: 22
Study 34073134 — intervention group
Group type: COMPARATOR
Intervention: Control group (19 °C)
Number of subjects: 22
Study 32000674 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-space technique (n=20)
Number of subjects: 40
Study 32000674 — intervention group
Group type: COMPARATOR
Intervention: Single-space technique (n=20)
Number of subjects: 40
Study 33508756 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic screening mammography (SM) plus digital breast tomosynthesis (DBT)
Number of subjects: 1206
Study 34318568 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured short intervention consisting of self-reflection, education on skin diseases, contact with a person with psoriasis, and case studies.
Number of subjects: 221
Study 34318568 — intervention group
Group type: COMPARATOR
Intervention: Control group attending regular lessons.
Number of subjects: 221
Study 35983682 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention + low-cost water filter pitcher
Number of subjects: 0
Study 35983682 — intervention group
Group type: COMPARATOR
Intervention: Only the filter
Number of subjects: 0
Study 33902816 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonverbal response card arm
Number of subjects: 1644
Study 33902816 — intervention group
Group type: COMPARATOR
Intervention: Conventional verbal response arm
Number of subjects: 1644
Study 35388626 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency oscillation (HFO)
Number of subjects: 319
Study 35388626 — intervention group
Group type: COMPARATOR
Intervention: Conventional ventilation (CV)
Number of subjects: 319
Study 34874887 — intervention group
Group type: EXPERIMENTAL
Intervention: Telerehabilitation (TR) program
Number of subjects: 50
Study 34874887 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UCG)
Number of subjects: 50
Study 34102253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1; ribociclib 600 mg/day, 3 weeks on, 1 week off)
Number of subjects: 726
Study 34102253 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (fulvestrant 500 mg, day 1 of each 28-day cycle plus day 15 of cycle 1)
Number of subjects: 726
Study 34102253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant (first-line setting)
Number of subjects: 726
Study 34102253 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (first-line setting)
Number of subjects: 726
Study 34102253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribociclib plus fulvestrant (second-line setting)
Number of subjects: 726
Study 34102253 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (second-line setting)
Number of subjects: 726
Study 36352146 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 376
Study 36352146 — intervention group
Group type: COMPARATOR
Intervention: Surgeon's choice of surgery
Number of subjects: 376
Study 34152420 — intervention group
Group type: EXPERIMENTAL
Intervention: Active VR
Number of subjects: 90
Study 34152420 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive VR
Number of subjects: 90
Study 34152420 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 90
Study 32182916 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA_MSA algorithm (combination of pixel-swapping algorithm and modified simulated annealing algorithm)
Number of subjects: 0
Study 32182916 — intervention group
Group type: EXPERIMENTAL
Intervention: PSA_MSA algorithm
Number of subjects: 0
Study 36401728 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin plus standard treatment
Number of subjects: 226
Study 36401728 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 226
Study 34362490 — intervention group
Group type: COMPARATOR
Intervention: Serum adenosine deaminase (ADA) levels in AL patients
Number of subjects: 123
Study 34362490 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ADA correlation with Hcy, ALT, AST, GGT, LDH in AML group
Number of subjects: 123
Study 34362490 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum ADA correlation with GGT in ALL group
Number of subjects: 123
Study 34362490 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for ADA in AML group
Number of subjects: 123
Study 34362490 — intervention group
Group type: EXPERIMENTAL
Intervention: ROC curve analysis for ADA in ALL group
Number of subjects: 123
Study 36078602 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure wristband at P6 point applied three times daily
Number of subjects: 90
Study 36078602 — intervention group
Group type: COMPARATOR
Intervention: Regular doses of intravenous antiemetics
Number of subjects: 90
Study 34270335 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrarapid lispro (URLi)
Number of subjects: 42
Study 34270335 — intervention group
Group type: COMPARATOR
Intervention: Lispro (Humalog®)
Number of subjects: 42
Study 32619713 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 660 nm, 15 mW, 3.8 J/cm2, starting on the first day of radiotherapy
Number of subjects: 73
Study 32619713 — intervention group
Group type: COMPARATOR
Intervention: Group 2: 660 nm, 25 mW, 6.3 J/cm2, starting on the first day of radiotherapy
Number of subjects: 73
Study 32619713 — intervention group
Group type: COMPARATOR
Intervention: Group 3: 660 nm, 15 mW, 3.8 J/cm2 for therapeutic purpose
Number of subjects: 73
Study 34396485 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini implants in conjunction with class II elastics
Number of subjects: 28
Study 34396485 — intervention group
Group type: COMPARATOR
Intervention: Class II elastics therapy (control group)
Number of subjects: 28
Study 34569426 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 IU HBIG + HBVac
Number of subjects: 331
Study 34569426 — intervention group
Group type: COMPARATOR
Intervention: 200 IU HBIG + HBVac
Number of subjects: 331
Study 34266402 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon ion radiotherapy alone (51 Gy in 17 fractions + boost of 15 Gy in 5 fractions)
Number of subjects: 314
Study 34266402 — intervention group
Group type: COMPARATOR
Intervention: Combined modality treatment (Photon IMRT 50 Gy in 25 fractions + boost using 8 × 3 Gy carbon ions)
Number of subjects: 314
Study 35712943 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheat grain moxibustion at Shixuan (EX‐UE 11) combined with rehabilitation training
Number of subjects: 80
Study 35712943 — intervention group
Group type: COMPARATOR
Intervention: Routine rehabilitation training
Number of subjects: 80
Study 32449567 — intervention group
Group type: EXPERIMENTAL
Intervention: Bowel rest
Number of subjects: 0
Study 32449567 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35710445 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquefied petroleum gas (LPG) for cooking
Number of subjects: 1854
Study 35710445 — intervention group
Group type: COMPARATOR
Intervention: Usual cooking practices
Number of subjects: 1854
Study 32861545 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24IU)
Number of subjects: 40
Study 32861545 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 34246347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib (400 mg once daily) plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Number of subjects: 1101
Study 34246347 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus abiraterone (1000 mg once daily) and prednisolone (5 mg twice a day)
Number of subjects: 1101
Study 34246347 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipatasertib-abiraterone
Number of subjects: 1101
Study 34246347 — intervention group
Group type: COMPARATOR
Intervention: Placebo-abiraterone
Number of subjects: 1101
Study 33227624 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 60
Study 33227624 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 34047723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac group (received standard-of-care protocol, intravenous ketorolac at completion of procedure, and oral ketorolac on discharge)
Number of subjects: 39
Study 34047723 — intervention group
Group type: COMPARATOR
Intervention: Control group (received standard-of-care pain protocol, including oxycodone-acetaminophen 5 to 325 mg on discharge)
Number of subjects: 39
Study 34047723 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac group
Number of subjects: 39
Study 34047723 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac group and Control group
Number of subjects: 39
Study 32311957 — intervention group
Group type: EXPERIMENTAL
Intervention: Yan Fu app for blood pressure management
Number of subjects: 480
Study 32311957 — intervention group
Group type: COMPARATOR
Intervention: Control group (no m-Health apps)
Number of subjects: 480
Study 32623539 — intervention group
Group type: EXPERIMENTAL
Intervention: LEaP playgroup
Number of subjects: 71
Study 34365104 — intervention group
Group type: EXPERIMENTAL
Intervention: LPC model (simplest model equivalent to logistic regression of histogram of individual percentage changes in seizure rate)
Number of subjects: 0
Study 34365104 — intervention group
Group type: COMPARATOR
Intervention: Traditional standard, median percent change (MPC)
Number of subjects: 0
Study 32660564 — intervention group
Group type: EXPERIMENTAL
Intervention: sc-LCPUFA (1.19 g/day)
Number of subjects: 73
Study 32660564 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 35657463 — intervention group
Group type: EXPERIMENTAL
Intervention: Gem/Cis with DEBIRI
Number of subjects: 48
Study 35657463 — intervention group
Group type: COMPARATOR
Intervention: Gem/Cis alone
Number of subjects: 48
Study 32985373 — intervention group
Group type: EXPERIMENTAL
Intervention: Moovosity™ programme (8-week intervention)
Number of subjects: 34
Study 32985373 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (8-week wait)
Number of subjects: 34
Study 33180910 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-virgin olive oil supplementation for 4 weeks
Number of subjects: 0
Study 36203486 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg Rimazolam
Number of subjects: 100
Study 36203486 — intervention group
Group type: COMPARATOR
Intervention: 0.4 mg/kg Rimazolam
Number of subjects: 100
Study 33441871 — intervention group
Group type: EXPERIMENTAL
Intervention: EST-SSR markers identified from de novo transcriptome sequencing, with a total of 5,555 EST-SSRs identified from 35,251 unigenes.
Number of subjects: 60